LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

LLY

977.17

+3.12%↑

JNJ

220.76

-0.16%↓

ABBV

202.8

+0.83%↑

UNH

379.75

+0.08%↑

AZN

183.54

+0.67%↑

Home・Aktien・Merck & Co Inc.

Merck & Co Inc.

Open

BrancheGesundheitswesen

112.35 1

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

111.24

Max

113.66

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.2B -4.2B
Verkäufe	-114M 16B
KGV Branchendurchschnitt	31.507 49.8
EPS	-1.28
Dividendenrendite	2.92
Gewinnspanne	-26.053
Angestellte	73,000
EBITDA	-6.2B -1.9B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+22.44% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	2.92% 2.25%
Nächstes Ergebnis	4. Aug. 2026
Nächste Dividendenausschüttung	7. Juli 2026
Nächstes Ex-Dividendendatum	15. Juni 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	7.1B 279B
Vorheriger Eröffnungskurs	111.35
Vorheriger Schlusskurs	112.35

Nachrichtenstimmung

By Acuity

49%

51%

150 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

76.03 / 83.28 Unterstützung & Widerstand

Merck & Co Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Apr. 2026, 14:20 UTC

Ergebnisse

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30. Apr. 2026, 10:45 UTC

Ergebnisse

Merck 1Q Sales Rise on Continued Keytruda Growth

5. Mai 2026, 18:12 UTC

Ergebnisse

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5. Mai 2026, 13:54 UTC

Ergebnisse

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5. Mai 2026, 12:48 UTC

Akquisitionen, Fusionen, Übernahmen

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5. Mai 2026, 12:48 UTC

Akquisitionen, Fusionen, Übernahmen

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5. Mai 2026, 12:47 UTC

Akquisitionen, Fusionen, Übernahmen

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5. Mai 2026, 12:45 UTC

Akquisitionen, Fusionen, Übernahmen

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1. Mai 2026, 18:35 UTC

Ergebnisse

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1. Mai 2026, 14:53 UTC

Ergebnisse

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30. Apr. 2026, 13:27 UTC

Ergebnisse

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30. Apr. 2026, 10:47 UTC

Ergebnisse

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck 1Q Animal Health Sales Up 13% >MRK

30. Apr. 2026, 10:30 UTC

Ergebnisse

Merck 1Q Sales $16.29B >MRK

Peer-Vergleich

Kursveränderung

Merck & Co Inc. Prognose

Kursziel

By TipRanks

22.44% Vorteil

12-Monats-Prognose

Durchschnitt 136.37 USD 22.44%

Hoch 179 USD

Tief 112 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Merck & Co Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

21 ratings

Buy

Halten

Sell

Basierend auf 21 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Merck & Co Inc. – Dist abgegeben haben.

Technischer Score

By Trading Central

76.03 / 83.28Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Stimmung

By Acuity

150 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.